Hints and tips:
...The government has vowed to tackle the price of cancer medicines, threatening revenues for multinationals such as Eli Lilly, Roche and Novartis....
...“Without positive action — a defined goal and a number within a timeframe — nothing happens,” says Funke Abimbola, general counsel and head of financial compliance at pharmaceutical company Roche UK, and...
...Roche’s Ocrevus for multiple sclerosis tops the list with a projected $3.3bn....
...In Japan, shares of Tokyo-based Chugai Pharmaceuticals rose 16 per cent after weekend reports suggested that Roche, its Swiss parent that owns a 60 per cent stake, is in talks to take full ownership....
...(Financial Times) Roche is to buy Santaris Pharma for up to $450m in the latest piece of dealmaking by the Swiss pharmaceuticals group....
...Roche is the second European pharmaceutical company in a week to have the US Food and Drug Administration question its medicines....
...“However, unlike some, we don’t feel that equities need a V-shaped profile to make further gains....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
International Edition